Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases (scientific article published on 13 March 2012)

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial

Q27851630

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Q30494798

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis

Q33903716

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

Q34398884

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

Q34613506

Receptor conversion in distant breast cancer metastases

Q34989060

Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss

Q35082619

HER2 gene status in primary breast cancers and matched distant metastases

Q35906294

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

Q36615272

Evaluating distant metastases in breast cancer: from biology to outcomes.

Q36933261

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

Q37316222

Prognostic factors in 1,038 women with metastatic breast cancer

Q37321930

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

Q37468681

Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance

Q43162626

One-time general consent for research on biological samples: opt out system for patients is optimal and endorsed in many countries

Q43242370

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

Q43447818

Progesterone receptor status of breast cancer metastases

Q43893980

Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies

Q46340745

Impact of metastatic estrogen receptor and progesterone receptor status on survival

Q46382088

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

Q46466675

HER-2/neu expression in primary and metastatic breast cancer

Q46754911

Should liver metastases of breast cancer be biopsied to improve treatment choice?

Q51054351

Variation in receptor status between primary and metastatic breast cancer.

Q54158344

Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy.

Q54400297

HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.

Q54614183

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

Q59567861

Estrogen and progesterone receptor concordance between primary and recurrent breast cancer

Q72736221

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

Q73388496

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

Q81527951

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

Q81565196

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

Q84566644

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

estrogen

Q277954

cancer metastasis

Q120912394

P304

page(s)

4929-4935

P577

publication date

2012-03-13

P1433

published in

Cancer

Q326041

P1476

title

Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases

P478

volume

118

Reverse relations

cites work (P2860)

Q36756685	An in vitro-in vivo model of epithelial mesenchymal transition in triple negative breast cancer
Q41346864	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.
Q35054455	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
Q35758871	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells
Q37011741	Breast cancer as a systemic disease: a view of metastasis
Q90619966	Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
Q37696668	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Q36756659	Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study
Q36545146	Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications
Q36924473	Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.
Q49558301	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Q41932946	Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation
Q38730755	Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals
Q37013898	ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Q58738574	FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome
Q90470271	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases
Q87371371	HIF-1α and NOTCH signaling in ductal and lobular carcinomas of the breast
Q36757904	Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients
Q90335058	Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study
Q39042654	IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype
Q41547969	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
Q35000639	Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells
Q64106622	Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
Q59791901	Moving Breast Cancer Therapy up a Notch
Q92281361	Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes
Q36265144	Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
Q35533772	Promoter hypermethylation profiling of distant breast cancer metastases
Q37687736	Receptor conversion in metastatic breast cancer: a prognosticator of survival
Q38736287	Role of steroid receptor and coregulator mutations in hormone-dependent cancers
Q39218132	The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
Q92799863	The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer
Q36336601	The changing role of ER in endocrine resistance
Q37702383	The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer
Q41612814	Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
Q37709430	Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study
Q34584209	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
Q33817285	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

P356	DOI	10.1002/CNCR.27518
P698	PubMed publication ID	22415862